ATHERSYS, INC / NEW Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2011-11-14: Form 8-K; Period of report 2011-11-11; Description 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition; Details 1.01.
- 2011-11-14: Form 8-K; Period of report 2011-11-11; Description 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; Details 1.01.
- 2011-08-10: Form 8-K; Period of report 2011-08-10; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2011-06-20: Form 8-K; Period of report 2011-06-16; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2011-11-14 | 8-K | 2011-11-11 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition | 1.01 On November 11, 2011, Athersys, Inc. and ABT Holding Company, a subsidiary of Athersys, Inc. (together, “Athersys” or the “Company”) entered into a Termination Agreement with Angiotech Pharmaceuticals, Inc. (“Angiotech”) to terminate the Strategic Alliance Agreement, License Agreement and ancillary agreements (the “Angiotech Agreements”) dated May 5, 2006 between the parties, reflecting a change in Angiotech’s business and financial strategy. 1.02 The discussion of the termination of the Angiotech Agreements included in Item 1.01 of this Current Report on Form 8-K is incorporated in this Item 1.02 by reference. 2.02 On November 14, 2011, Athersys issued a press release announcing financial results for its third quarter ended September 30, 2011. | c24691e8vk.htm |
| 2011-11-14 | 8-K | 2011-11-11 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 3.02 The information contained above in Item 1.01 is hereby incorporated by reference into this Item 3.02. | c24674e8vk.htm |
| 2011-08-10 | 8-K | 2011-08-10 | 2.02 Results of Operations and Financial Condition | 2.02 On August 10, 2011, Athersys, Inc. issued a press release announcing financial results for its second quarter ended June 30, 2011. | c21183e8vk.htm |
| 2011-06-20 | 8-K | 2011-06-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 On June 16, 2011, at the Annual Meeting of Stockholders of Athersys, Inc. (the “Company”), the Company’s stockholders approved and adopted the Athersys, Inc. 2007 Long-Term Incentive Plan (Amended and Restated Effective June 16, 2011) (the “Plan”). 5.07 The Company held its Annual Meeting of Stockholders on June 16, 2011. | c18885e8vk.htm |
| 2011-06-10 | 8-K | 2011-06-10 | 8.01 Other Events | 8.01 On June 10, 2011, Athersys, Inc. (the “Company”) announced positive results from the analysis of one-year follow-up data from its Phase I clinical trial of MultiStem®, its allogeneic adult stem cell product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. | c18610e8vk.htm |
| 2011-05-25 | 8-K | 2011-05-25 | 8.01 Other Events | 8.01 On May 25, 2011, Athersys, Inc. (the “Company”) announced interim results from its ongoing Phase I study of the Company’s MultiStem® for hematopoietic stem cell transplant (HSCT) support and graft-versus-host disease (GvHD). | c17834e8vk.htm |
| 2011-05-05 | 8-K | 2011-05-05 | 2.02 Results of Operations and Financial Condition | 2.02 On May 5, 2011, Athersys, Inc. issued a press release announcing financial results for its first quarter ended March 31, 2011. | c16470e8vk.htm |
| 2011-03-14 | 8-K | 2011-03-14 | 2.02 Results of Operations and Financial Condition | 2.02 On March 14, 2011, Athersys, Inc. issued a press release announcing financial results for its fourth quarter ended December 31, 2010. | c14023e8vk.htm |
| 2011-01-28 | 8-K | 2011-01-27 | 8.01 Other Events | 8.01 On January 27, 2011, the Company entered into a Placement Agency Agreement (the “Placement Agreement”) with William Blair & Company, L.L.C. and First Analysis Securities Corporation (together, the “Placement Agents”) pursuant to which the Placement Agents agreed to use their reasonable best efforts to arrange for the sale of up to 4,366,667 shares of the Company’s common stock, $0.001 par value per share (“Common Stock”), and warrants to purchase up to an additional 1,310,000 shares of Common Stock in a registered direct public offering (the “Offering”). | l41716e8vk.htm |
| 2011-01-25 | 8-K | 2011-01-19 | 8.01 Other Events | 8.01 On January 19, 2011, Athersys, Inc. (the “Company”), with Case Western Reserve University School of Medicine (the “School of Medicine”), announced that a joint scientific study on spinal cord injury was published in the January issue of The Journal of Neuroscience. | c11394e8vk.htm |
| 2011-01-20 | 8-K | 2011-01-14 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | c10987e8vk.htm | |
| 2011-01-03 | 8-K | 2010-12-31 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 31, 2010, Dr. Floyd Loop notified Athersys, Inc. (the “Company”) that he was resigning as a member of the Company’s Board of Directors, effective immediately. | c09529e8vk.htm |